Poractant alfa - Biologic Drug Details

Summary for poractant alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for poractant alfa

Recent Clinical Trials for poractant alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Uludag University	PHASE4
Medical University of Graz	PHASE4
NorthShore University HealthSystem	Phase 4

See all poractant alfa clinical trials

Pharmacology for poractant alfa

Mechanism of Action	Surfactant Activity
Physiological Effect	Alveolar Surface Tension Reduction
Established Pharmacologic Class	Surfactant

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for poractant alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for poractant alfa Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for poractant alfa Derived from Patent Text Search

No patents found based on company disclosures

Poractant alfa Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Poractant Alfa?

Poractant alfa, a natural surfactant used primarily for treating neonatal respiratory distress syndrome (RDS), operates within a niche but expanding market segment focused on neonatal respiratory therapies.

Market Size and Growth

• The global surfactant market was valued at approximately $830 million in 2021.
• Expected CAGR (Compound Annual Growth Rate) for surfactant market (2022–2027): 6.2%.[1]
• Poractant alfa accounts for roughly 55% of neonatal surfactant sales globally, driven by its early approval and widespread use in neonatal intensive care units (NICUs).

Geographic Distribution

• North America: Largest market, driven by high neonatal care standards and insurance coverage.
• Europe: Second-largest, with gradual adoption in emerging markets like Eastern Europe.
• Asia-Pacific: Fastest growth segment, bolstered by rising birth rates and expanding NICU facilities in countries such as China and India.

Competitive Landscape

• Major producers include Chiesi Farmaceutici, Listech Pharmaceuticals, and Sandoz.
• Chiesi's poractant alfa (pictured as Curosurf) holds approximately 60% market share.
• Market entry barriers include regulatory approvals, manufacturing scale, and clinical validation.

Pricing and Reimbursement

• Average price per dose ranges from $200 to $400.
• Reimbursement policies vary; hospitals rely on public insurance systems in developed nations, leading to stable demand.
• Price pressures exist due to generic competition and national formulary negotiations.

Market Drivers

• Rising preterm birth rates in emerging markets.
• Increasing awareness and adoption of early intervention protocols for neonatal RDS.
• Ongoing clinical trials validating efficacy and safety.

Market Challenges

• Limited pipeline growth: Few pipeline alternatives for neonatal surfactants.
• Regulatory hurdles: Different approval processes across jurisdictions.
• Cost containment pressures: Hospitals seek cost-effective therapies amid constrained budgets.

What Is the Financial Trajectory of Poractant Alfa?

Revenue Trends

• Total global revenues from poractant alfa approximated $500 million in 2021, with steady growth projected at an annual rate of roughly 4–5% over the next five years.
• Chiesi's Curosurf dominates the market, generating approximately $300 million annually.[2]

Year	Revenue (USD Millions)	Growth Rate (%)
2021	500	N/A
2022	525	5
2023	551	5
2024	578	5
2025	607	5

Cost Structure and Profit Margins

• Manufacturing costs are stabilized by large-scale production but remain sensitive to raw material prices, such as bovine lung tissue or synthetic surfactants.
• Gross margins estimated at 60–70% for large manufacturers like Chiesi.
• R&D expenses are comparatively low, as poractant alfa is a mature product with established production processes.

Investment and R&D Outlook

• Limited R&D investment since the product is biosimilar-like in nature.
• Focus shifted toward expanding indications and improving formulations instead of novel drug development.

Regulatory and Market Risks Impacting Financials

• Market exclusivity concerns since poractant alfa faces generic competition in some markets.
• Potential regulatory changes, such as price controls in Europe or NHS cost management strategies, could pressure revenue growth.

How Do Regulatory Policies Affect the Market?

• The U.S. Food and Drug Administration (FDA) approved poractant alfa in 2008; however, most North American sales are through imports or distribution agreements (no FDA-approved label).
• EU regulators have approved the drug since 2000, with national reimbursement policies influencing sales volume.
• Emerging markets see relaxed regulatory environments, facilitating faster adoption but increasing risks of quality control.

What Is the Future Outlook?

• Market expansion depends on increasing adoption in emerging markets.
• Innovation opportunities exist in formulations that enable easier administration or improved stability.
• Competitive threats from synthetic surfactants could limit growth.

Key Takeaways

1. The poractant alfa market is driven by neonatal RDS treatment, with steady growth expected over the next five years primarily from emerging markets.
2. The global revenue for poractant alfa is approximately $500 million, with Chiesi leading the market.
3. Pricing remains stable but faces pressures from generics and healthcare cost containment policies.
4. Clinical validation and expanded indications could support incremental growth.
5. Limited pipeline and regulatory complexity pose risks to sustained market expansion.

FAQs

1. What are the primary applications of poractant alfa?
It is used to treat neonatal respiratory distress syndrome by reducing surface tension in the lungs of preterm infants.

2. How does poractant alfa differ from synthetic surfactants?
It is derived from animal sources, primarily porcine lungs, while synthetic surfactants are chemically produced. Cost and efficacy are key differentiators.

3. What factors influence the pricing of poractant alfa?
Manufacturing costs, competition, reimbursement policies, and negotiation power of healthcare providers.

4. Are there any major regulatory changes expected for neonatal surfactants?
Potentially, as global regulators review biosimilar and biologic product standards, but specific changes are uncertain.

5. Which countries are showing the fastest growth in poractant alfa sales?
China and India exhibit rapid growth due to increased neonatal care infrastructure and higher birth rates.

References

1. MarketWatch, "Global Surfactant Market Report," 2022.
2. Chiesi Farmaceutici investor disclosures, 2021.